Arsenic, which can crosslink adjacent cysteines within the catalytic approach of UBE2O, could serve as the basis of an alternative approach to inhibiting E2 activity and is currently being tested against various forms of cancer in clinical trials (https://clinicaltrials.gov) [21,66]. The gene discussed is UBE2O; the disease is cancer.